Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma

NCT04200443 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

96

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Leiomyosarcoma
Metastatic Soft Tissue Sarcoma
Stage III Uterine Corpus Leiomyosarcoma AJCC v8
Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8
Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8
Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8
Stage IV Uterine Corpus Leiomyosarcoma AJCC v8
Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8
Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8
Unresectable Leiomyosarcoma
Unresectable Soft Tissue Sarcoma

Interventions

DRUG: Cabozantinib
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration
DRUG: Temozolomide

Sponsor

City of Hope Medical Center

Collaborators

National Cancer Institute (NCI)